INVENTAGE
LIVE

Serial Number

79266586

Owner

Inventage Lab Inc.

Attorney

Paul G. Johnson

Filing Date

Jul 5, 2019

Add to watchlist:

No watchlists yet
View on USPTO

INVENTAGE Trademark

Serial Number: 79266586 • Registration: 6071903

INVENTAGE is a trademark filed by Inventage Lab Inc. on July 5, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Inventage Lab Inc. (2 trademarks)

24 Dunchon-daero 388beon-gil, Jungwon-gu
Seongnam, Gyeonggi-do 13403 , KR

Entity Type: 03

Trademark Details

Filing Date

July 5, 2019

Registration Date

June 9, 2020

Published for Opposition

March 24, 2020

Goods & Services

Medicinal infusions for treating dementia, diabetes, obesity, andropathy, alopecia, incurable disease, chronic disease, lipolysis, and boosting the immune system; Medicinal infusions for treating dirofilaria immitis diseases, infectious diseases, skeletal and muscular disorders, cardiovascular and circulatory diseases, nervous system diseases, ocular disorders, respiratory diseases, gastrointestinal diseases, endocrine diseases, kidney diseases, hormonal diseases, and oncological diseases and disorders of animals; implantable medicines in the nature of surgical implants comprised of living tissues; pharmaceutical compositions for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical compositions for animal skincare; pharmaceutical compositions for skin care; pharmaceutical compositions for treating dirofilaria immitis diseases, infectious diseases, skeletal and muscular disorders, cardiovascular and circulatory diseases, nervous system diseases, ocular disorders, respiratory diseases, gastrointestinal diseases, endocrine diseases, kidney diseases, hormonal diseases, and oncological diseases and disorders of animals; medicines for human purposes, namely, medicines for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drugs in the nature of pharmaceutical preparations for medical purposes, namely, for the treatment of oncological, gastrointestinal, metabolic, chronic, endocrine, respiratory, neurological and ophthalmic diseases and disorders; therapeutic drugs and agents in the nature of therapeutic pharmaceutical and agents for the treatment of oncological, gastrointestinal, metabolic, chronic, endocrine, respiratory, neurological and ophthalmic diseases and disorders; therapeutic drugs and agents in the nature of therapeutic pharmaceutical and agents for treating dirofilaria immitis diseases, infectious diseases, skeletal and muscular disorders, cardiovascular and circulatory diseases, nervous system diseases, ocular disorders, respiratory diseases, gastrointestinal diseases, endocrine diseases, kidney diseases, hormonal diseases, and oncological diseases and disorders of animals; chemical preparations for pharmaceutical purposes, namely, for the treatment of oncological, gastrointestinal, metabolic, chronic, endocrine, respiratory, neurological and ophthalmic diseases and disorders

Medical apparatus and instruments for use in endovascular, cardiovascular, and endoscopy procedures; medical instruments for use in drug delivery systems; medical instruments for use in monitoring oxymetory, gas analysis, vital signs, blood properties and respiratory events; medical instruments for use in treating osteoarthritis, osteoporosis, osteotraumatic injuries, degenerative bone diseases and joint diseases; medical instruments to measure blood pressure, cardiac output and other physiological and cardiovascular parameters; medical instruments for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; medical filler apparatus in the nature of synthetic filler and extender material to serve as replacement for bone; medical apparatus and instruments, namely, infusion and injection devices for administering pharmaceuticals; diagnostic apparatus and instruments for medical purposes, namely, medical diagnostic apparatus for testing blood sugar levels, cancer cells, DNA, urinary protein, and cholesterol level; injection device for pharmaceuticals; medical apparatus, namely, infusion and injection devices for administering pharmaceuticals

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 9, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Jan 28, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 25, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 2, 2020 FICS
FINAL DISPOSITION PROCESSED
Oct 2, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 9, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 9, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 24, 2020 NPUB
PUBLISHED FOR OPPOSITION
Mar 24, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 14, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 24, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2020 TROA
REFUSAL PROCESSED BY IB
Oct 19, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 1, 2019 RFCS
REFUSAL PROCESSED BY MPU
Oct 1, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 25, 2019 RFCR
NON-FINAL ACTION WRITTEN
Sep 24, 2019 CNRT
ASSIGNED TO EXAMINER
Sep 23, 2019 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 17, 2019 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 12, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 5, 2019 REPR